Sandia Biotech is a bioreagent company that specializes in fluorescent technology. They have developed a novel type of biofluorescent antibodies called FluorAbodies®. FluorAbodies enhance biological research by providing a more affordable and accurate solution for fluorescence-based applications such as immunofluorescence, microscopy, and flow cytometry.
“Partnering with NMSBA and Sandia allowed us to validate the performance of our FluorAbodies with robust data. This collaboration has been key in accelerating our path to market and demonstrating the value our technology brings to researchers.”
Tony Pino
President
Sandia Biotech Inc.
Sandia Biotech wanted to analyze the unique properties of its FluorAbodies to gather data that would show the new products’ benefits to their target market. They connected with the NMSBA Program and gained access to the expertise of Bioscience team Bryce Ricken and Stephanie Kolker at Sandia National Laboratories. Using the Labs’ specialized equipment, fluorescent plate reader, and other fluorescent imaging capabilities, Ricken was able to document the absorbance and emission spectrum of several of the company’s FluorAbodies.
The data demonstrates that Sandia Biotech’s patented production methodology reduces variation between lots in its FluorAbodies. This complements their other advantages, like their monovalent design, reduced size, and multiplexing capabilities (the ability to simultaneously measure multiple elements in the same experiment). Their unique design also streamlines experimental protocols, helping researchers save valuable time.
Data from the NMSBA project has helped the company increase customer interest. Sandia Biotech markets its products worldwide directly through its website, www.sandiabio.com, and is in talks with distributors now, using the data to show how impactful this new class of fluorescent antibodies can be to research. FluorAbodies should be on the market soon, at least in part, thanks to the assistance from NMSBA.